Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer.

[2] Michael Pehl was named CEO in December 2017 but left for personal reasons in February 2019.

[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.

[4] In October 2020, Gilead Sciences acquired the company.

[1] In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains.